The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity

Trends Cancer. 2018 Nov;4(11):784-792. doi: 10.1016/j.trecan.2018.09.001. Epub 2018 Sep 29.


Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset, conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient survival and, in preclinical models, is critical for the spontaneous rejection of immunogenic cancers and for the success of T cell-based immunotherapies. The unique role of cDC1 reflects the ability to initiate de novo T cell responses after migrating to tumor-draining lymph nodes, as well as to attract T cells, secrete cytokines, and present tumor antigens within the tumor microenvironment, enhancing local cytotoxic T cell function. Strategies aimed at increasing cDC1 abundance in tumors and enhancing their functionality provide attractive new avenues to boost anti-tumor immunity and overcome resistance to cancer immunotherapies.

Keywords: cDC1; cancer immunity; dendritic cells; immune evasion; immunotherapy; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Dendritic Cells / immunology*
  • Humans
  • Lymph Nodes / immunology
  • Neoplasms / immunology*
  • T-Lymphocytes / immunology


  • Antigens, Neoplasm